{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:40:44Z","timestamp":1792197644129,"version":"4.4.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"DOI":"10.1007\/s40271-026-00847-w","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:57:23Z","timestamp":1792195043000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Qualitative Exit Interviews to Characterize the Positive Treatment Experiences of Patients in the Phase III Trial of Orforglipron Versus Oral Semaglutide for the Treatment of Type 2 Diabetes"],"prefix":"10.1007","author":[{"given":"Kristina","family":"Boye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelyn","family":"Cutts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youna","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliza","family":"Steere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Gelhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"key":"847_CR1","unstructured":"Centers for Disease Control and Prevention. Type 2 diabetes. 2024. https:\/\/www.cdc.gov\/diabetes\/about\/about-type-2-diabetes.html. Accessed 30 Jul 2025."},{"issue":"17","key":"847_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176275","volume":"21","author":"U Galicia-Garcia","year":"2020","unstructured":"Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, et al. Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci. 2020;21(17):6275. https:\/\/doi.org\/10.3390\/ijms21176275.","journal-title":"Int J Mol Sci"},{"key":"847_CR3","doi-asserted-by":"publisher","first-page":"117955142312207","DOI":"10.1177\/11795514231220780","volume":"16","author":"S Chakraborty","year":"2023","unstructured":"Chakraborty S, Verma A, Garg R, Singh J, Verma H. Cardiometabolic risk factors associated with type 2 diabetes mellitus: a mechanistic insight. Clin Med Insights Endocrinol Diabetes. 2023;16:11795514231220780. https:\/\/doi.org\/10.1177\/11795514231220780.","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"key":"847_CR4","unstructured":"Eli Lilly and Company. Highlights of prescribing information: Trulicity. 2025. https:\/\/pi.lilly.com\/us\/trulicity-uspi.pdf. Accessed 6 Jan 2026."},{"key":"847_CR5","unstructured":"Eli Lilly and Company. Highlights of prescribing information: Mounjaro. 2025. https:\/\/pi.lilly.com\/us\/mounjaro-uspi.pdf. Accessed 6 Jan 2026."},{"key":"847_CR6","unstructured":"Novo Nordisk Inc. Highlights of prescribing information: Rybelsus. 2025. https:\/\/www.novo-pi.com\/rybelsus.pdf. Accessed 6 Jan 2026."},{"issue":"9","key":"847_CR7","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.2337\/dc19-0749","volume":"42","author":"VR Aroda","year":"2019","unstructured":"Aroda VR, Rosenstock J, Terauchi Y, Altuntas Y, Lalic NM, Morales Villegas EC, et al. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019;42(9):1724\u201332. https:\/\/doi.org\/10.2337\/dc19-0749.","journal-title":"Diabetes Care"},{"issue":"10534","key":"847_CR8","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(26)00202-3","volume":"407","author":"J Rosenstock","year":"2026","unstructured":"Rosenstock J, Yabe D, Cox D, Li J, Denning M, Wu W-S, et al. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. Lancet. 2026;407(10534):1147\u201360.","journal-title":"Lancet"},{"key":"847_CR9","unstructured":"US Food and Drug Administration. Patient-focused drug development: collecting comprehensive and representative input. 2020. https:\/\/www.fda.gov\/media\/139088\/download. Accessed Oct 2025."},{"key":"847_CR10","unstructured":"European Medicines Agency. Reflection paper on patient experience data. 2025. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-patient-experience-data_en.pdf. Accessed 6 Jan 2026."},{"key":"847_CR11","unstructured":"US Food and Drug Administration. Patient-focused drug development: methods to identify what is important to patients. 2022. https:\/\/www.fda.gov\/media\/131230\/download. Accessed Oct 2025."},{"issue":"3","key":"847_CR12","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s40271-025-00730-0","volume":"18","author":"C Carmichael","year":"2025","unstructured":"Carmichael C, Jouravskaya I, Collins E, Burns D, Poon JL, Kitchen H, et al. Patient experience of treatment with tirzepatide for weight management: exit interviews from SURMOUNT-4. Patient (Auckl). 2025;18(3):225\u201336. https:\/\/doi.org\/10.1007\/s40271-025-00730-0.","journal-title":"Patient (Auckl)"},{"issue":"3","key":"847_CR13","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40271-022-00578-8","volume":"15","author":"LS Matza","year":"2022","unstructured":"Matza LS, Stewart KD, Lando LF, Patel H, Boye KS. Exit interviews examining the patient experience in clinical trials of tirzepatide for treatment of type 2 diabetes. Patient. 2022;15(3):367\u201377. https:\/\/doi.org\/10.1007\/s40271-022-00578-8.","journal-title":"Patient"},{"key":"847_CR14","unstructured":"Lilly. Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial. 2025. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-oral-glp-1-orforglipron-superior-oral-semaglutide-head. Accessed Oct 2025."},{"key":"847_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2025.100220","volume":"16","author":"IA Goetz","year":"2025","unstructured":"Goetz IA, Kanu C, Hoover A, Jimenez-Moreno C, Karn H, Kimel M, et al. Perceived benefits of treatment for obesity with retatrutide: a qualitative study of patients in a phase 2 clinical trial. Obes Pillars. 2025;16:100220. https:\/\/doi.org\/10.1016\/j.obpill.2025.100220.","journal-title":"Obes Pillars."},{"issue":"7","key":"847_CR16","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jval.2017.11.014","volume":"21","author":"DM Turner-Bowker","year":"2018","unstructured":"Turner-Bowker DM, Lamoureux RE, Stokes J, Litcher-Kelly L, Galipeau N, Yaworsky A, et al. Informing a priori sample size estimation in qualitative concept elicitation interview studies for clinical outcome assessment instrument development. Value Health. 2018;21(7):839\u201342. https:\/\/doi.org\/10.1016\/j.jval.2017.11.014.","journal-title":"Value Health"},{"key":"847_CR17","unstructured":"ATLAS.ti Scientific Software Development GmbH. User manual: ATLAS.ti Windows. 2022. https:\/\/doc.atlasti.com\/ManualWin.v22\/ATLAS.ti_ManualWin.v22.pdf. Accessed 6 Jan 2026."},{"key":"847_CR18","doi-asserted-by":"publisher","unstructured":"American Diabetes Association Professional Practice Committee. 8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes-2025. Diabetes Care. 2025;48(1 Suppl. 1):S167\u201380. https:\/\/doi.org\/10.2337\/dc25-S008.","DOI":"10.2337\/dc25-S008"},{"issue":"9","key":"847_CR19","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1007\/s13300-023-01426-0","volume":"14","author":"KS Boye","year":"2023","unstructured":"Boye KS, Stewart KD, Matza LS. Development of a patient-reported outcome (PRO) measure to assess emotional impact of treatment for type 2 diabetes. Diabetes Ther. 2023;14(9):1451\u201370. https:\/\/doi.org\/10.1007\/s13300-023-01426-0.","journal-title":"Diabetes Ther"},{"issue":"12","key":"847_CR20","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1089\/dia.2012.0123","volume":"14","author":"RP Hayes","year":"2012","unstructured":"Hayes RP, Schultz EM, Naegeli AN, Curtis BH. Test-retest, responsiveness, and minimal important change of the ability to perform physical activities of daily living questionnaire in individuals with type 2 diabetes and obesity. Diabetes Technol Ther. 2012;14(12):1118\u201325. https:\/\/doi.org\/10.1089\/dia.2012.0123.","journal-title":"Diabetes Technol Ther"},{"issue":"3","key":"847_CR21","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1089\/dia.2014.0142","volume":"17","author":"RP Hayes","year":"2015","unstructured":"Hayes RP, DeLozier AM. Reliability, validity, and responsiveness of the Impact of Weight on Self-Perceptions Questionnaire (IW-SP) in individuals with type 2 diabetes and obesity. Diabetes Technol Ther. 2015;17(3):210\u20134. https:\/\/doi.org\/10.1089\/dia.2014.0142.","journal-title":"Diabetes Technol Ther"},{"issue":"1","key":"847_CR22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s41687-023-00614-7","volume":"7","author":"KD Stewart","year":"2023","unstructured":"Stewart KD, Matza LS, Patel H, Boye KS. Development of a patient-reported outcome (PRO) measure to assess patient perceptions of simplicity and complexity of treatment for type 2 diabetes. J Patient Rep Outcomes. 2023;7(1):89. https:\/\/doi.org\/10.1186\/s41687-023-00614-7.","journal-title":"J Patient Rep Outcomes."},{"key":"847_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-5-57","volume":"5","author":"C Bradley","year":"2007","unstructured":"Bradley C, Plowright R, Stewart J, Valentine J, Witthaus E. The Diabetes Treatment Satisfaction Questionnaire change version (DTSQc) evaluated in insulin glargine trials shows greater responsiveness to improvements than the original DTSQ. Health Qual Life Outcomes. 2007;5:57. https:\/\/doi.org\/10.1186\/1477-7525-5-57.","journal-title":"Health Qual Life Outcomes"},{"key":"847_CR24","unstructured":"Casagrande SS, Gary-Webb TL. Sociodemographic characteristics of youth and adults with diabetes. In: Lawrence JM, Casagrande SS, Herman WH, Wexler DJ, Cefalu WT, editors. Diabetes in America. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); 2023."}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-026-00847-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40271-026-00847-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-026-00847-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:57:24Z","timestamp":1792195044000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40271-026-00847-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":24,"alternative-id":["847"],"URL":"https:\/\/doi.org\/10.1007\/s40271-026-00847-w","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"18 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Katelyn Cutts, Eliza Steere, and Heather Gelhorn work for Thermo Fisher Scientific, who was paid by Eli Lilly and Company to conduct the study. Kristina Boye and Youna Zhao are employees and shareholders for Eli Lilly and Company.","order":1,"name":"Ethics","label":"Conflicts of interest\/competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by Salus Institutional Review Board under study number 24360.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data from this study may be made available upon reasonable request and with permission from Eli Lilly and Company.","order":3,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conception and design: KB, KC, YZ, ES, and HG. Acquisition of data: KB, KC, YZ, ES, and HG. Analysis and interpretation of data: KB, KC, YZ, ES, and HG. Initial drafting of article: KC and HG. Revising intellectual content of article: KB, KC, YZ, ES, and HG. Final approval of article: KB, KC, YZ, ES, and HG.","order":5,"name":"Ethics","label":"Authors\u2019 contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}